- $1.56bn
- $1.29bn
- $16.10m
UniQure plunges as Huntington's trial data disappoints investors (updated)
uniQure tumbles after updated Huntington's disease gene therapy data
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
uniQure seeks US approval for Huntington's gene therapy after FDA reversal
uniQure rises after FDA filing for Huntington's gene therapy
Trump picks White House adviser Heidi Overton to run FDA, source says (updated)
UniQure climbs as FDA deems accelerated approval filing 'reasonable' for Huntington's therapy
Biotech experts want FDA drug reviews based on science, not politics (updated)
Biotech experts want FDA drug reviews based on science, not politics
UniQure dips after share sale swells to $225 mln
UniQure rises as it seeks equity raise following FDA about-face
Brief: Uniqure Announces $150 Million Proposed Public Offering
UniQure starts $150 mln equity offering following FDA U-turn
Brief: Uniqure Announces Preliminary Data On First Cohort In Phase I/IIA Clinical Trial Of AMT-260
UniQure gains after FDA green lights Huntington's gene therapy filing
UniQure gains after FDA green lights Huntington's gene therapy filing
NASDAQ RESUMED AT 07:55 AM
UniQure to seek approval for Huntington's therapy after FDA U-turn, shares skyrocket (updated)
UniQure gets FDA green light to file for Huntington's gene therapy approval